Picato (ingenol mebutate) – Suspension of the marketing authorisation due to risk of skin malignancy

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Active substance
Ingenol mebutate
Therapeutic area (MeSH)
Keratosis, Actinic
Procedure number
EMEA/H/A-20/1489/C/2275/1489
Regulatory outcome
Suspension
DHPC type
  • Interim measures
  • Referral - Article 20 procedure
Referral name
Picato
Human ATC code
D06BX02
Dissemination date
27/01/2020
Related medicines

How useful was this page?

Add your rating